The liver diseases therapeutics
market had value over USD 7,498.0 million in 2014. The major driving factors
are increasing numbers of liver diseases like hepatocellular carcinoma and vast
unexploited need of patients with these types of diseases. In addition,
increasing geriatric population globally is estimated to augment the market
demand in the future period.
Huge expenditure by
biotechnology and pharmaceutical industries on R&D and availability of
sturdy pipeline are the major expected boosting factors for the growth of liver
diseases therapeutics market in future period. Governments’ and big companies’
vaccination program are creating awareness about the illness and prevention is
boosting the growth of the market.
The market is bifurcated into
products and regions. New products are rapidly being launched boosting the
market growth. The growth of the market is boosted by the strategic alliances,
joint venture between the major players, and growing awareness of healthcare in
the upcoming nations.
In depth research report on Liver Diseases Therapeutics
Market
Nonetheless, risks and side
effects linked with existing medication & stringent FDA and other norms
approved by the government along with accessibility of varying treatment
measures perform as barriers to the industry. The market was dominated by the
antiviral drug sector with a value over USD 2631 million in revenue terms in
2014.
Rising population with liver
diseases due to increasing number of alcohol consumers is estimated to boost
the market share. Alternatively, the antiviral drug is estimated to observer
profitable raise of over 8.8% from 2015 to 2022. This is due to the occurrence
of drugs in the pipeline.
The market is estimated to be
at over USD 12095.0 million by 2022. This is going to happen due to the
increasing geriatric population, rising liver ailments like hepatocellular and
hepatitis carcinoma along with high requirement for programs on vaccination in developing
nations and high spending on growing healthcare in the developed nations.
North America is dominating the
global market due to academic and research institutions performing studies
related to medical trials. North America had more than 39% share of the global
market in 2014 and is anticipated to carry on leading till 2022. Asia Pacific
had share over USD 1615.5 million in 2014 and is estimated at CAGR over 8.5% in
the future.
Few of the major industries are
Abbott Laboratories, Gilead Sciences, Astellas Pharma Inc., GlaxoSmithKline
plc, Bristol-Mayers Squibb, and Merck & Co., Inc.
Browse more research reports of this category:
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
For more market analysis reports, please visit: http://www.grandviewresearch.com/
No comments:
Post a Comment